These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2729 related items for PubMed ID: 21535989

  • 21. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    Lee SE, Min CK, Yahng SA, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Park CW.
    Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
    [Abstract] [Full Text] [Related]

  • 22. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.
    Martin TJ, Ng KW.
    J Cell Biochem; 1994 Nov; 56(3):357-66. PubMed ID: 7876329
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.
    Arthritis Res; 1999 Nov; 1(1):81-91. PubMed ID: 11056663
    [Abstract] [Full Text] [Related]

  • 26. The cellular actions of interleukin-11 on bone resorption in vitro.
    Hill PA, Tumber A, Papaioannou S, Meikle MC.
    Endocrinology; 1998 Apr; 139(4):1564-72. PubMed ID: 9528935
    [Abstract] [Full Text] [Related]

  • 27. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N, Colla S, Rizzoli V.
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [Abstract] [Full Text] [Related]

  • 28. Osteoblast function in myeloma.
    Roodman GD.
    Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
    [Abstract] [Full Text] [Related]

  • 29. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD.
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [Abstract] [Full Text] [Related]

  • 30. New potential targets for treating myeloma bone disease.
    Roodman GD.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
    [Abstract] [Full Text] [Related]

  • 31. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O.
    Biochem Biophys Res Commun; 2005 Dec 16; 338(2):687-93. PubMed ID: 16216218
    [Abstract] [Full Text] [Related]

  • 32. Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity.
    Kanatani M, Sugimoto T, Nishiyama K, Chihara K.
    J Bone Miner Res; 2000 May 16; 15(5):902-10. PubMed ID: 10804020
    [Abstract] [Full Text] [Related]

  • 33. Discovery, Development, and clinical applications of bortezomib.
    Jung L, Holle L, Dalton WS.
    Oncology (Williston Park); 2004 Dec 16; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [Abstract] [Full Text] [Related]

  • 34. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.
    Cancer Res; 2007 Jan 01; 67(1):202-8. PubMed ID: 17210700
    [Abstract] [Full Text] [Related]

  • 35. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD.
    Br Med Bull; 2014 Sep 01; 111(1):117-38. PubMed ID: 25190762
    [Abstract] [Full Text] [Related]

  • 36. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD.
    Bone; 2008 Apr 01; 42(4):669-80. PubMed ID: 18294945
    [Abstract] [Full Text] [Related]

  • 37. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E.
    Expert Opin Ther Targets; 2009 Jul 01; 13(7):839-48. PubMed ID: 19530987
    [Abstract] [Full Text] [Related]

  • 38. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J, Cibeira MT, Rosiñol L.
    Acta Oncol; 2005 Jul 01; 44(5):440-8. PubMed ID: 16118077
    [Abstract] [Full Text] [Related]

  • 39. Morphology and biochemistry of bone remodeling: possible control by vitamin D, parathyroid hormone, and other substances.
    Huffer WE.
    Lab Invest; 1988 Oct 01; 59(4):418-42. PubMed ID: 3050272
    [Abstract] [Full Text] [Related]

  • 40. Pathogenesis of myeloma bone disease.
    Roodman GD.
    Leukemia; 2009 Mar 01; 23(3):435-41. PubMed ID: 19039321
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 137.